Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
There are conflicting recommendations on whether to use or not to use fluoroquinolone prophylaxis in pediatric oncology patients. An international pediatric clinical practice guideline (CPG) recommends administering levofloxacin prophylaxis in patients with acute myeloblastic leukemia and relapsed acute lymphoblastic leukemia receiving intensive chemotherapy as this practice has been found to reduce episodes of fever and bacteremia. A separate European CPG does not recommend levofloxacin prophylaxis because of concerns for adverse effects, including potentiation of fluoroquinolone resistance and possible increased resistance to other classes of antibiotics. The nuance of the decision to give or not give prophylaxis is discussed in the context of published evidence defining the risks and benefits of levofloxacin prophylaxis for pediatric leukemia patients at high risk for bacterial infection. Knowledge gaps are also identified to guide further investigations to optimize the use of fluoroquinolone prophylaxis in pediatric patients receiving chemotherapy for cancer or undergoing a hematopoietic cell transplantation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jpids/piae077 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel chromogenic medium-based method for the rapid detection of drug resistance.
World J Gastroenterol
August 2025
Guangxi Zhuang Autonomous Region Engineering Research Center of Clinical Prevention and Control Technology and Leading Drug for Microorganisms with Drug Resistance in Border Ethnic Areas, Youjiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China.
Background: (), a globally prevalent pathogen, is exhibiting increasing rates of antimicrobial resistance. However, clinical implementation of pre-treatment susceptibility testing remains limited due to the organism's fastidious growth requirements and prolonged culture time.
Aim: To propose a novel detection method utilizing antibiotic-supplemented media to inhibit susceptible strains, while resistant isolates were identified through urease-mediated hydrolysis of urea, inducing a phenol red color change for visual confirmation.
In vivo pharmacokinetic and pharmacodynamic profiles of orbifloxacin against Staphylococcus aureus in a neutropenic murine thigh infection model.
BMC Vet Res
August 2025
State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Background: Orbifloxacin is a broad-spectrum fluoroquinolone antibiotic developed for veterinary use in the treatment of skin and soft tissue infections, as well as respiratory tract infections. This study aimed to define the pharmacokinetic/pharmacodynamic (PK/PD) indices and target exposures associated with antibacterial activity, thereby providing a rational framework for the development and optimization of orbifloxacin dosing regimens in the treatment of infections.
Results: The PK profiles and PK/PD relationship of orbifloxacin against were investigated using a neutropenic murine thigh infection model with multiple dosing regimens.
Achieving optimal uptake of TB preventive treatment for rifampin-resistant and/or multidrug-resistant TB.
Int J Tuberc Lung Dis
August 2025
Boston University School of Public Health, Department of Epidemiology, Boston, Massachusetts, USA.
With clinical trials establishing the efficacy of levofloxacin preventive treatment for exposure to multi-drug resistant/rifampin-resistant TB, national programs are in the process of updating their guidelines for programmatic roll-out. However, national programs need to carefully consider contextual barriers and enablers to achieve optimal uptake of this preventive treatment for household and close contacts. Creating a patient-centered environment and engaging stakeholders across the spectrum of care will ensure equitable access and help to realise the full potential of this treatment.
View Article and Find Full Text PDFOutbreak Caused by VIM-1- and VIM-4-Positive in a Hospital in Zagreb.
Pathogens
July 2025
Department of Clinical Microbiology, Dr Andrija Štampar Teaching Institute of Public Health Zagreb, 10000 Zagreb, Croatia.
Background/objectives: is a frequent causative agent of urinary and wound infections in both community and hospital settings. It develops resistance to expanded-spectrum cephalosporins (ESCs) due to the production of extended-spectrum β-lactamases (ESBLs) or plasmid-mediated AmpC β-lactamases (p-AmpCs). Recently, carbapenem-resistant isolates of emerged due to the production of carbapenemases, mostly belonging to Ambler classes B and D.
View Article and Find Full Text PDFImpact of Antibiotic Prophylaxis Duration on the Incidence of Healthcare-Associated Infections in Elective Colorectal Surgery.
Antibiotics (Basel)
August 2025
Department for Surgery with Anesthesiology, Faculty of Medicine, University of Belgrade, Dr Subotica No. 8, 11000 Belgrade, Serbia.
: Antibiotic prophylaxis is a key component of infection prevention strategies. This study aimed to evaluate whether the duration of antibiotic prophylaxis influences the incidence of HAIs in patients undergoing elective colorectal surgery. : This prospective cohort study included 278 adult patients who underwent elective colorectal surgery at a single tertiary care center.
View Article and Find Full Text PDF